Market news

Motley Fool Press Release.

Detailed price information for Airsculpt Technologies Inc (AIRS-Q) from The Globe and Mail including charting and trades.

AirSculpt Technologies (AIRS) is back in focus after reporting Q2 2026 results that showed slightly lower sales and a wider net loss, while management reaffirmed full year revenue guidance at the lower end of its range. See our latest analysis for AirSculpt Technologies. The Q2 2026 earnings release and reaffirmed revenue outlook have landed after a period of sharp share price swings for AirSculpt Technologies, with the stock up strongly year to date but total shareholder return over the past...

AirSculpt®, the leader in minimally invasive body contouring, today announced the first national partnership with Tiger Aesthetics™ for alloClae™, an off-the-shelf structural adipose tissue designed for aesthetic body procedures. Launching in August across select AirSculpt locations, the rollout reflects AirSculpt's commitment to expand availability nationwide by the end of 2026.

Despite a 2.5% revenue dip, the company posts its second consecutive quarter of case growth and expands its procedure portfolio to capture the GLP-1 market.

AirSculpt Technologies (NASDAQ:AIRS) is seeing stabilization in its core body-contouring business after several quarters of declines, while expanding services aimed at patients using GLP-1 weight-loss drugs, Chief Executive Officer Yogi Jashnani said at a Canaccord consumer conference. The company

US stocks mixed, Dow Jones down 0.2% midday. Energy shares up 3%, real estate down 1.4%. National Energy Services up 16% on strong earnings.

AirSculpt Technologies (NASDAQ:AIRS) reported second-quarter revenue of $42.9 million, down 2.5% from the prior-year period, as the company cited stable revenue trends, positive same-center case growth and continued investment in marketing and expanded procedure offerings. Chief Executive Officer Y

Summary: U.S. stock futures mixed, Dow futures down 0.1%. AirSculpt Technologies shares fell 13.4% after reporting Q2 results in-line with estimates. Other stocks moving lower in pre-market trading include NAMI, BNED, YXT, TENX, MSC, B, VRSK, XFOR, HELP, and SLDB.

Same Center Cases Up 1% for the Second Consecutive Quarter...

Company to Participate in Canaccord Genuity's 46th Annual Growth Conference...